I'm Scott Goldsmith. I treat multiple myeloma patients out at City of Hope in Duarte, California. And I'm here at ASH, first time attending ASH since I became a member of faculty. And so it's a very different experience. I'm presenting a poster on single cell sequencing in patients on their peripheral blood and then overlaying it with some of their minimal residual disease testing to see if we can detect their specific myeloma at a very deep level in the peripheral blood and if that correlates at all with their treatment outcomes. And then a number of other people from our division are presenting here. Dr. Krishnan is presenting on some bismacific antibodies. We have a translational group, Dr. Pichiori, who's presenting some of her work on deratumum and resistance. So really strong showing from our myeloma division from City of Hope out here at ASH. So happy to be a part of that. As far as what I'm most interested to see here at ASH, there are a number of translational research presentations, oral abstracts and posters that are focusing on advanced multiple myeloma and relapse after some of our novel immune therapies. And so I'm most interested to see what these translational groups have uncovered to see if we can find ways to either prevent resistance or treat myeloma after it's become resistant to some of these generally pretty amazing therapies. There are also a number of phase two and three clinical trials, which I think the data will be important to have. But what really gets me going is the translational research and how we can continue to advance the field.
HealthTree • December 11, 2022